Cited 5 times in
2LBA Late Breaking - Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.